van Ingen 2010

Study characteristics
Patient sampling	Cross-sectional design with convenience-based enrolment of participants, retrospective data collection
Patient characteristics and setting	Country of origin: Netherlands World Bank classification of country: high Type of lab: reference Type of patients: confirmed MDR-TB cases, confirmed MDR-TBs with some known second-line resistance
Index tests	Manufacturer involvement: no Type of testing: indirect
Target condition and reference standard(s)	Culture (solid; 7H10) FQ drugs: moxifloxacin (1 µg/mL) SLIDs: amikacin (5 µg/mL) and capreomycin (10 µg/mL). WHO critical concentrations not used for 7H10 solid culture Discrepant analysis: no
Flow and timing	Uninterpretable results reported: yes
Comparative
Notes	Relevant clinical information? unclear
Methodological quality
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled?	No
Was a case-control design avoided?	No
Did the study avoid inappropriate exclusions?	Yes
			High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
If a threshold was used, was it pre-specified?	Yes
			Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition?	No
Were the reference standard results interpreted without knowledge of the results of the index tests?	Yes
			Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes